SSY Group (HKG:2005) obtained production and registration approval for the Aminophylline Tablets from China's National Medical Products Administration to become a bulk drug for preparations on the market, a Monday Hong Kong bourse filing said.
The move came as the drug is regarded as passing the regulator's consistency evaluation.
The drug is mainly used to relieve wheezing symptoms in bronchial asthma, wheezing bronchitis, and obstructive emphysema, and to treat asthma caused by cardiogenic pulmonary edema.